BiogenBIIB
BIIB
About: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Employees: 7,605
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
24% more repeat investments, than reductions
Existing positions increased: 325 | Existing positions reduced: 263
22% more first-time investments, than exits
New positions opened: 127 | Existing positions closed: 104
1% more funds holding
Funds holding: 855 [Q4 2024] → 863 (+8) [Q1 2025]
3.4% less ownership
Funds ownership: 90.14% [Q4 2024] → 86.74% (-3.4%) [Q1 2025]
14% less capital invested
Capital invested by funds: $20.1B [Q4 2024] → $17.4B (-$2.72B) [Q1 2025]
44% less call options, than puts
Call options by funds: $345M | Put options by funds: $621M
50% less funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 2 (-2) [Q1 2025]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$115
10%
downside
Avg. target
$182
42%
upside
High target
$255
99%
upside
8 analyst ratings
5 positive
63%
3 neutral
38%
0 negative
0%
RBC Capital Brian Abrahams | 67%upside $213 | Outperform Reiterated | 27 Jun 2025 |
HC Wainwright & Co. Andrew Fein | 46%upside $187 | Buy Reiterated | 26 Jun 2025 |
Piper Sandler David Amsellem | 10%downside $115 | Neutral Reiterated | 12 Jun 2025 |
Wedbush Laura Chico | 5%downside $121 | Neutral Reiterated | 12 Jun 2025 |
Mizuho Salim Syed | 32%upside $169 | Outperform Maintained | 7 May 2025 |
Financial journalist opinion
Based on 11 articles about BIIB published over the past 30 days
Positive
Zacks Investment Research
1 day ago
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.
Neutral
GlobeNewsWire
4 days ago
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for ZURZUVAE® (zuranolone) for the treatment of postpartum depression (PPD) in adults following childbirth. If approved by the European Commission (EC), ZURZUVAE will be the first treatment authorized within the European Union specifically indicated to treat depressive symptoms for women with PPD. ZURZUVAE is a once-daily, oral, 14-day treatment which was approved by the U.S. Food and Drug Administration (FDA) in 2023.
Negative
Zacks Investment Research
5 days ago
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 week ago
Biogen to Highlight Scientific Progress Across Alzheimer's Disease at the Alzheimer's Association International Conference 2025
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.
Positive
Benzinga
1 week ago
Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing
Biogen Inc. BIIB said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park (RTP).
Positive
Reuters
1 week ago
Biogen to invest $2 billion more in North Carolina
Drugmaker Biogen said on Monday it will invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park.
Neutral
GlobeNewsWire
1 week ago
Biogen Announces $2 Billion Manufacturing Investment in North Carolina's Research Triangle Park in Conjunction with its 30th Anniversary
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park (RTP). Since breaking ground in 1995, Biogen's manufacturing in RTP has played a vital role in delivering the company's pipeline and portfolio of innovative treatments for millions of patients around the world. Biogen has invested approximately $10 billion in its North Carolina manufacturing footprint to date, including more than $3 billion in recent years, and this upcoming investment will fuel the continued advancement of Biogen's late-stage clinical pipeline.
Neutral
Business Wire
2 weeks ago
Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evaluated the potential effects of the Phase 3 zorevunersen dosing regimen. The data are complementary to previously reported data from a.
Neutral
GlobeNewsWire
2 weeks ago
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress
– Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BEDFORD, Mass.
Negative
Zacks Investment Research
4 weeks ago
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.
Charts implemented using Lightweight Charts™